Use of Long-Acting Injectable (LAI) aripiprazole during pregnancy A case series about baby and children neurodevelopment
Abstract
Introduction The perinatal period is associated with an increased risk of relapse in schizophrenia which can lead to long-term implications for the wellbeing of mother and baby. Long-Acting Injectable (LAI) antipsychotics have proven useful for relapse prevention in schizophrenia, but their use during pregnancy is still conflicting among clinical guidelines Objectives We aimed at reporting a case series on the use of LAI aripiprazole during pregnancy in three women with schizophrenia during their pregnancies, with the derived obstetric neonatal and neurodevelopment outcomes. Informed consent to publish this case series was obtained from patients Methods Description and review of neurodevelopment outcomes in babies exposed to LAI aripiprazole during pregnancy Results We present three cases of pregnant women with schizophrenia. They are in treatment with LAI aripiprazole 400mg/28 days with clinical stability during their pregnancy. One patient presented two pregnancies with LAI aripiprazole treatment. Two of them didn’t take folic acid during the first trimester. Obstetric follow-up did not reveal obstetric complications or foetus malformations during both pregnancies. Patients maintained psychopathologic stability throughout pregnancies and postpartum periods. Bayley scale was evaluated, no adverse effects were reported in two babies, nevertheless, the other two presented mild-moderate deficit in social communication. After 6 years these two kids have psychological follow-up…
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.